{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T20:36:57Z","timestamp":1721162217647},"reference-count":95,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2003,8]]},"DOI":"10.1016\/s0093-7754(03)00252-5","type":"journal-article","created":{"date-parts":[[2003,9,8]],"date-time":"2003-09-08T18:47:00Z","timestamp":1063046820000},"page":"465-475","source":"Crossref","is-referenced-by-count":32,"title":["HLA class II antibodies in the treatment of hematologic malignancies"],"prefix":"10.1016","volume":"30","author":[{"given":"Michael","family":"Dechant","sequence":"first","affiliation":[]},{"given":"Joerg","family":"Bruenke","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Valerius","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0093-7754(03)00252-5_bib1","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nm0102-68","article-title":"Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning","volume":"8","author":"Shipp","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/S0093-7754(03)00252-5_bib2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0952-7915(99)00010-2","article-title":"Signaling antibodies in cancer therapy","volume":"11","author":"Cragg","year":"1999","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/74621","article-title":"Monoclonal antibody therapies\u2014A \u2018constant\u2019 threat to cancer","volume":"6","author":"Houghton","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/S0093-7754(03)00252-5_bib4","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0008-8749(89)90257-8","article-title":"Antiproliferative mechanism of anti-class II monoclonal antibodies","volume":"119","author":"Vaickus","year":"1989","journal-title":"Cell Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib5","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1038\/nm0802-781","article-title":"DR\u2019s orders: Human antibody kills tumors by direct signaling","volume":"8","author":"Longo","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/S0093-7754(03)00252-5_bib6","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1056\/NEJM200009073431006","article-title":"The HLA system. First of two parts","volume":"343","author":"Klein","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/S0093-7754(03)00252-5_bib7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0092-8674(00)81025-9","article-title":"Invariant chain structure and MHC class II function","volume":"84","author":"Cresswell","year":"1996","journal-title":"Cell"},{"key":"10.1016\/S0093-7754(03)00252-5_bib8","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1006\/cimm.1993.1309","article-title":"HLA class II-mediated aggregation is associated with the proliferation of B lymphocytes","volume":"152","author":"Ramirez","year":"1993","journal-title":"Cell Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib9","article-title":"Analysis of 1D10 antigen expression in human malignant tissues: implications for clinical use of Hu1D10","author":"Wang","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib10","doi-asserted-by":"crossref","first-page":"8581","DOI":"10.1073\/pnas.90.18.8581","article-title":"Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization","volume":"90","author":"Roche","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0093-7754(03)00252-5_bib11","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1042\/bj3200293","article-title":"Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas","volume":"320","author":"Hansen","year":"1996","journal-title":"Biochem J"},{"key":"10.1016\/S0093-7754(03)00252-5_bib12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm0697-682","article-title":"Monoclonal antibodies against the 4\u20131BB T-cell activation molecule eradicate established tumors","volume":"3","author":"Melero","year":"1997","journal-title":"Nat Mednmn"},{"key":"10.1016\/S0093-7754(03)00252-5_bib13","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/5505","article-title":"CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help","volume":"5","author":"French","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/S0093-7754(03)00252-5_bib14","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.4049\/jimmunol.164.4.2160","article-title":"Engagement of the OX-40 receptor in vivo enhances antitumor immunity","volume":"164","author":"Weinberg","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1084\/jem.194.4.481","article-title":"Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy","volume":"194","author":"van Elsas","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/S0093-7754(03)00252-5_bib16","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1084\/jem.20011925","article-title":"Fc\u03b3 receptors and cross-presentation in dendritic cells","volume":"195","author":"Amigorena","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/S0093-7754(03)00252-5_bib17","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0167-5699(94)90271-2","article-title":"MHC class II signaling in B-cell activation","volume":"15","author":"Scholl","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/S0093-7754(03)00252-5_bib18","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/intimm\/6.6.887","article-title":"Lymphocyte programmed cell death is mediated via HLA class II DR","volume":"6","author":"Truman","year":"1994","journal-title":"Int Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib19","doi-asserted-by":"crossref","first-page":"10459","DOI":"10.1073\/pnas.90.22.10459","article-title":"Ligation of major histocompatibility complex class II molecules mediates apoptotic cell death in resting B lymphocytes","volume":"90","author":"Newell","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0093-7754(03)00252-5_bib20","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0304-3835(98)00034-2","article-title":"Selective apoptosis of neoplastic cells by the HLA-DR-specific monoclonal antibody","volume":"128","author":"Vidovic","year":"1998","journal-title":"Cancer Lett"},{"key":"10.1016\/S0093-7754(03)00252-5_bib21","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1002\/eji.1830250811","article-title":"Ligation of HLA class II molecules promotes sensitivity to CD95 (Fas antigen, APO-1)-mediated apoptosis","volume":"25","author":"Yoshino","year":"1995","journal-title":"Eur J Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib22","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1182\/blood.V89.6.1996","article-title":"ULA class II-mediated death is induced via Fas\/Fas ligand interactions in human splenic B lymphocytes","volume":"89","author":"Truman","year":"1997","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0198-8859(02)00384-1","article-title":"HLA class II signals sensitize B lymphocytes to apoptosis via Fas\/CD95 by increasing FADD recruitment to activated Fas and activation of caspases","volume":"63","author":"Blancheteau","year":"2002","journal-title":"Hum Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib24","doi-asserted-by":"crossref","first-page":"5115","DOI":"10.4049\/jimmunol.151.10.5115","article-title":"Cross-linking of HLA class II antigens modulates the release of tumor necrosis factor-\u03b1 by the EBV-B lymphoblastoid cell line JY","volume":"151","author":"Altomonte","year":"1993","journal-title":"J Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib25","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.4049\/jimmunol.163.8.4115","article-title":"A caspase-independent pathway of MHC class II antigen-mediated apoptosis of human B lymphocytes","volume":"163","author":"Drenou","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1006\/cimm.1998.1428","article-title":"Triggering HLA-DR molecules on human peripheral monocytes induces their death","volume":"192","author":"Thibeault","year":"1999","journal-title":"Cell Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0198-8859(00)00240-8","article-title":"HLA-DR mediated cell death is associated with, but not induced by TNF-\u03b1 secretion in APC","volume":"62","author":"Bertho","year":"2001","journal-title":"Hum Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib28","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nm736","article-title":"Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells","volume":"8","author":"Nagy","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/S0093-7754(03)00252-5_bib29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1365-3083.2001.00969.x","article-title":"Signalling via MHC class II molecules modifies the composition of GEMs in APC","volume":"54","author":"Setterblad","year":"2001","journal-title":"Scand J Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib30","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/intimm\/dxf058","article-title":"MHC class II-mediated apoptosis of mature dendritic cells proceeds by activation of the protein kinase C-delta isoenzyme","volume":"14","author":"Bertho","year":"2002","journal-title":"Int Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib31","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/ijc.1366","article-title":"Humanization and characterization of the anti-HLA-DR antibody 1D10","volume":"93","author":"Kostelny","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/S0093-7754(03)00252-5_bib32","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1046\/j.1365-2141.2002.03722.x","article-title":"Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10\u2014A humanized human leucocyte antigen DR antibody","volume":"118","author":"Stockmeyer","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib33","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1053\/sonc.2002.30156","article-title":"Rituximab: Mechanism of action and resistance","volume":"29","author":"Maloney","year":"2002","journal-title":"Semin Oncol"},{"issue":"suppl 1","key":"10.1016\/S0093-7754(03)00252-5_bib34","first-page":"611a","article-title":"A role of the mitochondrial apoptosis inducing-factor in Hu1D10-mediated apoptosis","volume":"98","author":"Bains","year":"2001","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/S0093-7754(03)00252-5_bib35","first-page":"386a","article-title":"Hu1D10 induces parallel death and survival signals in chronic lymphocytic leukemia (CLL) cells: Justification for combination studies of Hu1D10 with PI3 kinase inhibitors","volume":"100","author":"Mone","year":"2002","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib36","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1182\/blood.V98.5.1352","article-title":"Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma","volume":"98","author":"Weng","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib37","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib38","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","article-title":"Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts","volume":"101","author":"Cragg","year":"2003","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib39","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1034\/j.1600-065X.2002.18912.x","article-title":"Clustering of MHC-peptide complexes prior to their engagement in the immunological synapse: lipid raft and tetraspan microdomains","volume":"189","author":"Vogt","year":"2002","journal-title":"Immunol Rev"},{"key":"10.1016\/S0093-7754(03)00252-5_bib40","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1182\/blood-2002-03-0687","article-title":"Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing","volume":"100","author":"Dechant","year":"2002","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3233\/HAB-1995-6204","article-title":"A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system","volume":"6","author":"Hu","year":"1995","journal-title":"Hum Antibodies Hybridomas"},{"key":"10.1016\/S0093-7754(03)00252-5_bib42","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1182\/blood.V75.12.2408.2408","article-title":"Interferon \u03b3 augments Lym-1-dependent, granulocyte-mediated tumor cell lysis","volume":"75","author":"Vaickus","year":"1990","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib43","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1182\/blood.V87.9.3803.bloodjournal8793803","article-title":"HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor","volume":"87","author":"Elsasser","year":"1996","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib44","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1182\/blood.V93.10.3505.410k20_3505_3511","article-title":"Monoclonal Lym-1 antibody-dependent cytolysis by neutrophils exposed to granulocyte-macrophage colony-stimulating factor: intervention of Fc\u03b3RII (CD32), CD11b-CD18 integrins, and CD66b glycoproteins","volume":"93","author":"Ottonello","year":"1999","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib45","first-page":"3051","article-title":"Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells","volume":"58","author":"Wurflein","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/S0093-7754(03)00252-5_bib46","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev.iy.09.040191.002325","article-title":"Fc receptors","volume":"9","author":"Ravetch","year":"1991","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/jlb.49.5.511","article-title":"Biology of human immunoglobulin G Fc receptors","volume":"49","author":"van de Winkel","year":"1991","journal-title":"J Leukoc Biol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib48","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.290.5489.84","article-title":"Immune inhibitory receptors","volume":"290","author":"Ravetch","year":"2000","journal-title":"Science"},{"key":"10.1016\/S0093-7754(03)00252-5_bib49","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1182\/blood.V87.9.3813.bloodjournal8793813","article-title":"Bispecific-armed, interferon \u03b3-primed macrophage-mediated phagocytosis of malignant non-Hodgkin\u2019s lymphoma","volume":"87","author":"Ely","year":"1996","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib50","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.4049\/jimmunol.140.10.3467","article-title":"Modulation of human polymorphonuclear leukocyte IgG Fc receptors and Fc receptor-mediated functions by IFN-\u03b3 and glucocorticoids","volume":"140","author":"Petroni","year":"1988","journal-title":"J Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib51","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood.V78.4.885.885","article-title":"Neutrophils express the high affinity receptor for IgG (Fc\u03b3RI, CD64) after in vivo application of recombinant human granulocyte colony- stimulating factor","volume":"78","author":"Repp","year":"1991","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib52","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/blood.V82.3.931.931","article-title":"Involvement of the high-affinity receptor for IgG (Fc\u03b3RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy","volume":"82","author":"Valerius","year":"1993","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib53","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1054\/bjoc.2001.1940","article-title":"Chimaeric Lym-1 monoclonal antibody-mediated cytolysis by neutrophils from G-CSF-treated patients: stimulation by GM-CSF and role of Fc\u03b3-receptors","volume":"85","author":"Ottonello","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/S0093-7754(03)00252-5_bib54","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1182\/blood.V90.11.4485","article-title":"Fc\u03b1RI (CD89) as a novel trigger molecule for bispecific antibody therapy","volume":"90","author":"Valerius","year":"1997","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib55","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1042\/bj2710285","article-title":"The structure and function of human IgA","volume":"271","author":"Kerr","year":"1990","journal-title":"Biochem J"},{"key":"10.1016\/S0093-7754(03)00252-5_bib56","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/gut.44.1.2","article-title":"Intestinal IgA: Novel views on its function in the defence of the largest mucosal surface","volume":"44","author":"Mestecky","year":"1999","journal-title":"Gut"},{"key":"10.1016\/S0093-7754(03)00252-5_bib57","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1040-8428(01)00105-6","article-title":"IgA antibodies for cancer therapy","volume":"39","author":"Dechant","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib58","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.4049\/jimmunol.168.7.3275","article-title":"Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicity (ADCC)","volume":"168","author":"Tiroch","year":"2002","journal-title":"J Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib59","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/S0952-7915(99)00015-1","article-title":"Bispecific antibodies in cancer therapy","volume":"11","author":"Segal","year":"1999","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib60","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1040-8428(00)00135-9","article-title":"Preclinical and clinical data with bispecific antibodies recruiting myeloid effector cells for tumor therapy","volume":"38","author":"van Ojik","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib61","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1146\/annurev.immunol.21.120601.141011","article-title":"IgA Fc Receptors","volume":"21","author":"Monteiro","year":"2003","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib62","doi-asserted-by":"crossref","first-page":"5954","DOI":"10.4049\/jimmunol.165.10.5954","article-title":"Triggering Fc\u03b1-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy","volume":"165","author":"Stockmeyer","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib63","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1073\/pnas.80.9.2713","article-title":"In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor","volume":"80","author":"Waldor","year":"1983","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0093-7754(03)00252-5_bib64","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1084\/jem.158.4.1362","article-title":"Anti I-A antibody suppresses active encephalomyelitis: treatment model for diseases linked to IR genes","volume":"158","author":"Sriram","year":"1983","journal-title":"J Exp Med"},{"key":"10.1016\/S0093-7754(03)00252-5_bib65","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1084\/jem.156.2.480","article-title":"Conversion of immunity to suppression by in vivo administration of I-A subregion-specific antibodies","volume":"156","author":"Perry","year":"1982","journal-title":"J Exp Med"},{"key":"10.1016\/S0093-7754(03)00252-5_bib66","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1073\/pnas.81.9.2855","article-title":"Disappearance and reappearance of B cells after in vivo treatment with monoclonal anti-I-A antibodies","volume":"81","author":"Waldor","year":"1984","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0093-7754(03)00252-5_bib67","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.4049\/jimmunol.134.6.3597","article-title":"In vivo treatment of neonatal mice with anti-I-A antibodies interferes with the development of the class I, class II, and Mls-reactive proliferating T cell subset","volume":"134","author":"Kruisbeek","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib68","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.4049\/jimmunol.134.6.3605","article-title":"In vivo treatment with monoclonal anti-I-A antibodies: Disappearance of splenic antigen-presenting cell function concomitant with modulation of splenic cell surface I-A and I-E antigens","volume":"134","author":"Kruisbeek","year":"1985","journal-title":"J Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib69","doi-asserted-by":"crossref","first-page":"830","DOI":"10.4049\/jimmunol.136.3.830","article-title":"In vivo treatment with anti-I-A antibodies: differential effects on Ia antigens and antigen-presenting cell function of spleen cells and epidermal Langerhans cells","volume":"136","author":"Aberer","year":"1986","journal-title":"J Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib70","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.4049\/jimmunol.139.12.4242","article-title":"Selective in vivo antitumor effects of monoclonal anti-I-A antibody on B cell lymphoma","volume":"139","author":"Bridges","year":"1987","journal-title":"J Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib71","first-page":"5377","article-title":"Synergistic antitumor effects of interleukin 2 and the monoclonal Lym-1 against human Burkitt lymphoma cells in vitro and in vivo","volume":"49","author":"Gill","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/S0093-7754(03)00252-5_bib72","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1182\/blood.V90.8.3160","article-title":"Antitumor effects of nonconjugated murine Lym-2 and human-mouse chimeric CLL-1 monoclonal antibodies against various human lymphoma cell lines in vitro and in vivo","volume":"90","author":"Funakoshi","year":"1997","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/S0093-7754(03)00252-5_bib73","first-page":"576a","article-title":"Lym-1 unlabeled monoclonal antibody: effects on human B cell lymphoma cells in vitro and in human lymphoma cell\/Scid mouse model","volume":"100","author":"Smith","year":"2002","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib74","first-page":"71","article-title":"Efficacy and toxicity of 67Cu-2IT-BAT-Lym-1 radioimmunoconjugate in mice implanted with human Burkitt\u2019s lymphoma (Raji)","volume":"3","author":"DeNardo","year":"1997","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S0093-7754(03)00252-5_bib75","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1089\/cbr.1998.13.351","article-title":"Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts","volume":"13","author":"O\u2019Donnell","year":"1998","journal-title":"Cancer Biother Radiopharm"},{"key":"10.1016\/S0093-7754(03)00252-5_bib76","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood-2002-08-2629","article-title":"The anti-CD22 ligand blocking antibody, HB22.7, has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts","volume":"101","author":"Tuscano","year":"2003","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib77","first-page":"1505","article-title":"Therapy of disseminated B-cell lymphoma xenografts in severe combined immunodeficient mice with an anti-CD74 antibody conjugated with (111)indium, (67)gallium, or (90)yttrium","volume":"7","author":"Ochakovskaya","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S0093-7754(03)00252-5_bib78","doi-asserted-by":"crossref","first-page":"3544","DOI":"10.1182\/blood.V96.10.3544","article-title":"Therapeutic efficacy of Fc\u03b3RI\/CD64-directed bispecific antibodies in B-cell lymphoma","volume":"96","author":"Honeychurch","year":"2000","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/019262339902700101","article-title":"Pharmacology and safety assessment of humanized monoclonal antibodies for therapeutic use","volume":"27","author":"Klingbeil","year":"1999","journal-title":"Toxicol Pathol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib80","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1080\/10428190290026376","article-title":"In vivo pharmacodynamic effects of Hu1D10 (Remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells","volume":"43","author":"Shi","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/S0093-7754(03)00252-5_bib81","first-page":"830","article-title":"Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B- lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential","volume":"47","author":"Epstein","year":"1987","journal-title":"Cancer Res"},{"key":"10.1016\/S0093-7754(03)00252-5_bib82","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0161-5890(99)00083-8","article-title":"Critical Lym-1 binding residues on polymorphic HLA-DR molecules","volume":"36","author":"Rose","year":"1999","journal-title":"Mol Immunol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib83","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/hon.2900070207","article-title":"A phase 1a clinical trial of Lym-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies","volume":"7","author":"Hu","year":"1989","journal-title":"Hematol Oncol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib84","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1040-8428(01)00108-1","article-title":"The role of radiolabeled antibodies in the treatment of non-Hodgkin\u2019s lymphoma: The coming of age of radioimmunotherapy","volume":"39","author":"Goldenberg","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib85","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1200\/JCO.1998.16.10.3246","article-title":"Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin\u2019s lymphoma","volume":"16","author":"DeNardo","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0093-7754(03)00252-5_bib86","doi-asserted-by":"crossref","first-page":"118","DOI":"10.3816\/CLM.2000.n.010","article-title":"Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non- Hodgkin\u2019s lymphoma","volume":"1","author":"DeNardo","year":"2000","journal-title":"Clin Lymphoma"},{"key":"10.1016\/S0093-7754(03)00252-5_bib87","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood.V75.12.2375.2375","article-title":"Identification and characterization of a new surface membrane antigen found predominantly on malignant B lymphocytes","volume":"75","author":"Gingrich","year":"1990","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib88","article-title":"Phase I study of Hu1D10 monoclonal antibody (Remitogen) in patients with B-cell lymphoma","author":"Link","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/S0093-7754(03)00252-5_bib89","first-page":"244b","article-title":"Prolonged clinical responses in patients with follicular lymphoma treated on a phase I trial of the anti-HLA-DR monoclonal antibody Remitogen (Hu1D10)","volume":"98","author":"Link","year":"2001","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/S0093-7754(03)00252-5_bib90","first-page":"802a","article-title":"A phase I dose escalation study of apolizumab (Hu1D10) using a stepped up dosing schedule in patients with chronic lymphocytic leukemia (CLL) and acute lymphocytic leukemia (ALL)","volume":"100","author":"Lin","year":"2002","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/S0093-7754(03)00252-5_bib91","first-page":"358a","article-title":"Phase I study of combination rituximab (CD20) and apolizumab (Hu1D10) monoclonal antibody therapy in previously treated B-cell lymphoma and chronic lymphocytic leukemia","volume":"100","author":"Hegde","year":"2002","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/S0093-7754(03)00252-5_bib92","first-page":"606a","article-title":"A phase II study of Remitogen (Hu1D10), a humanized monoclonal antibody in patients with relapsed or refractory follicular, small lymphocytic, or marginal zone\/MALT B-cell lymphoma","volume":"98","author":"Link","year":"2001","journal-title":"Blood"},{"key":"10.1016\/S0093-7754(03)00252-5_bib93","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/74704","article-title":"Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets","volume":"6","author":"Clynes","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/S0093-7754(03)00252-5_bib94","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphisms in IgG Fc receptor Fc(\u03b3) RIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/S0093-7754(03)00252-5_bib95","first-page":"353a","article-title":"Analysis of IgG Fc receptor Fc\u03b3RIIIa polymorphism in relapsed follicular non-Hodgkin\u2019s lymphoma patients treated with rituximab","volume":"100","author":"Weng","year":"2002","journal-title":"Blood"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775403002525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775403002525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T21:52:01Z","timestamp":1682545921000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775403002525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8]]},"references-count":95,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["S0093775403002525"],"URL":"https:\/\/doi.org\/10.1016\/s0093-7754(03)00252-5","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2003,8]]}}}